Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: Steve Smith who wrote (14839)	1/20/2000 7:27:00 PM
From: IEarnedIt	Read Replies (2) \| Respond to of 118717

BINC is a JSB pick to the thread. I will let him do the honors. He has been the table pounder on this one. I am in it on his rec. (and my own DD of course) Now if you want to know more about digl or edig, fire away:-))))) JD

To: Steve Smith who wrote (14839)	1/20/2000 9:10:00 PM
From: JSB	Respond to of 118717

Steve, BINC has several patents on D-tagatose, a full bulk, low calorie, sugar substitute. Dtag was created by Dr. Levin, the CEO of BINC. BINC licensed the production rights to MD Foods of Denmark because Dtag is produced from whey, a dairy byproduct. Here is where it gets interesting, BINC only licensed to MDFI the rights to produce Dtag as a food additive. Dtag also has several other uses, the most important of which, is for use with Diabetics. Basicly, all we are waiting for is the declaration of GRAS (Generally regarded as safe). Dtag does not require FDA approval beyond GRAS, which is a self affirmation process. The panel of scientists retained my MDFI asked for on more study which was begun in the 4th qtr of 1999 and should be completed shortly, if it hasn't been already. As a food additive, Dtag is unique since there is no aftertaste and it is stable at high temperatures so that it can be used in baking. Additionally, it really does taste just like sugar. Dtag could be produced and sold right now in all parts of the world with the exception of the U.S. MDFI's strategy is to get GRAS and start here, though other markets could also be huge. As a biotech co, even without GRAS, BINC is very undervalued. Hope all this helps, Jeff